Robert W. Baird Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price

Spyre Therapeutics (NASDAQ:SYRE) had its price target lifted by investment analysts at Robert W. Baird from $65.00 to $90.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 42.25% from the stock’s previous close.

SYRE has been the subject of a number of other research reports. Mizuho upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. BTIG Research upped their price target on shares of Spyre Therapeutics from $70.00 to $98.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen cut shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Finally, Jefferies Financial Group upped their price target on shares of Spyre Therapeutics from $47.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $79.17.

Spyre Therapeutics Stock Performance

Shares of Spyre Therapeutics stock opened at $63.27 on Tuesday. The company has a market cap of $4.97 billion, a P/E ratio of -30.42 and a beta of 2.93. Spyre Therapeutics has a one year low of $12.04 and a one year high of $75.00. The firm has a fifty day moving average of $42.43 and a two-hundred day moving average of $32.74.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). As a group, equities analysts predict that Spyre Therapeutics will post -4.46 earnings per share for the current year.

Insider Transactions at Spyre Therapeutics

In related news, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $49.33, for a total value of $739,950.00. Following the sale, the chief executive officer directly owned 627,540 shares of the company’s stock, valued at approximately $30,956,548.20. This represents a 2.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sheldon Sloan sold 7,958 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $50.00, for a total transaction of $397,900.00. Following the completion of the sale, the insider directly owned 7,958 shares in the company, valued at approximately $397,900. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 62,958 shares of company stock valued at $2,734,375 in the last ninety days. 15.43% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Spyre Therapeutics

Large investors have recently added to or reduced their stakes in the business. HighVista Strategies LLC grew its stake in Spyre Therapeutics by 91.3% in the 3rd quarter. HighVista Strategies LLC now owns 215,746 shares of the company’s stock valued at $3,616,000 after acquiring an additional 102,941 shares during the last quarter. AlphaQuest LLC grew its stake in Spyre Therapeutics by 1,485.1% in the 3rd quarter. AlphaQuest LLC now owns 66,163 shares of the company’s stock valued at $1,109,000 after acquiring an additional 61,989 shares during the last quarter. Candriam S.C.A. grew its stake in Spyre Therapeutics by 64.4% in the 3rd quarter. Candriam S.C.A. now owns 404,362 shares of the company’s stock valued at $6,777,000 after acquiring an additional 158,332 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Spyre Therapeutics by 483.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 275,984 shares of the company’s stock valued at $4,625,000 after acquiring an additional 228,705 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its stake in Spyre Therapeutics by 59.6% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,000,000 shares of the company’s stock valued at $16,760,000 after acquiring an additional 373,297 shares during the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Topline SKYLINE trial results: SPY001 Part A met its primary endpoint with a statistically significant improvement in ulcerative colitis induction outcomes — the company described the data as “potential best‑in‑class,” driving bullish investor reaction. Read More.
• Positive Sentiment: Analyst upgrades and higher price targets: Leerink raised its target from $49 to $106 with an “outperform” rating, and BTIG bumped its target to $98 with a “buy” rating — these actions can attract momentum buyers and support the rally. Read More. Read More.
• Neutral Sentiment: Trading halt for news pending: Nasdaq temporarily halted SYRE trading prior to the data/announcement release, a regulatory pause that often precedes major corporate news and can amplify volatility when trading resumes.
• Neutral Sentiment: Full transcript and event details are available for investors who want granular trial data and management commentary; these can clarify durability, safety, and next steps that will influence medium‑term sentiment. Read More.
• Negative Sentiment: $300 million common stock offering announced: Spyre commenced an underwritten public offering of $300.0M of shares (with a 30‑day option for an additional $45.0M). Issuance of new shares can be dilutive and prompted a sell‑off in early trading. Read More. Read More.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.